---
company: DENTSPLY SIRONA Inc.
ticker: XRAY
form: 8-K/A
filed: 2026-08-07
accession: 0000818479-26-000263
source: https://www.sec.gov/Archives/edgar/data/818479/000081847926000263/
---

# DENTSPLY SIRONA (XRAY) earnings release, August 7, 2026

DENTSPLY SIRONA Inc. (XRAY) · Form 8-K/A, Item 2.02 · Filed 2026-08-07 · [SEC filing](https://www.sec.gov/Archives/edgar/data/818479/000081847926000263/)

Dentsply Sirona Reports Second Quarter 2026

Results

News Summary

• Reported net sales of $898 million

• Delivered GAAP gross margin of 54.9%, GAAP diluted earnings per share of $0.18

• Achieved adjusted gross margin of 56.4%, adjusted EBITDA margin of 21.3%, adjusted EPS of $0.52

• Announced expanded partnership with Medline Sinclair, broadening access to Connected Technology Solutions portfolio across Canada

• Repurchased 1.3 million shares of common stock during the quarter

• Reiterates 2026 outlook for net sales and adjusted EPS

Charlotte, N.C., August 6, 2026 -

DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the second quarter of 2026.

"2026 continues to be a year of decisive action as we execute our Return-to-Growth Action Plan," said Dan Scavilla, President and Chief Executive Officer of Dentsply Sirona. "We are making meaningful progress in our highest priority areas, including strengthening and expanding our distributor relationships, realigning our sales teams, and reinvesting in the business. Our second quarter results were in line with expectations and we continue to strengthen the financial foundation of the company. As our work gains traction, we remain focused on executing our strategy with discipline to drive sustained, profitable growth."

Q2 2026 Summary Results (Reported)

Q2 2026 Summary Results (Non-GAAP)

NM - not meaningful

Percentages are based on actual values and may not reconcile due to rounding.

[1]

Weighted-average shares outstanding used to calculate diluted loss per share for the second quarter of 2025 excludes potential dilutive common shares.

Q2 2026 Results by Region and Segment (Reported and Non-GAAP)

(in millions, except percentages)

Cash Flow and Liquidity

Operating cash flow in the second quarter of 2026 was $99 million, compared to $48 million in the second quarter of 2025, primarily due to the receipt of approximately $44 million in tariff refunds and improved management of inventory and accounts payable. Free cash flow, a Non-GAAP measure, in the second quarter of 2026 was $55 million compared to $16 million in the second quarter of 2025. The Company repurchased 1.3 million shares of its common stock for a total of approximately $12 million in the second quarter of 2026. The Company had $239 million of cash and cash equivalents as of June 30, 2026.

2026 Outlook

The Company is maintaining its 2026 outlook for net sales in the range of $3.5 billion to $3.6 billion and adjusted EPS in the range of $1.40 to $1.50. The benefits of refunds for tariffs are not included in the outlook for 2026 adjusted EPS.

We are unable to present a quantitative reconciliation of our expected earnings per diluted share to expected adjusted earnings per diluted share as we are unable to predict with reasonable certainty and without unreasonable effort, items which may include, but are not limited to, restructuring charges, transformation-related costs, impairment charges, certain tax adjustments, and other significant items. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Operations.

Conference Call/Webcast Information

Dentsply Sirona's management team will host an investor conference call and live webcast on August 6, 2026, at 4:30 p.m. ET. The live webcast and a presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com.

For those planning to participate on the call, please register at https://register-conf.media-server.com/register/BIa20adbc738174810a6f4b3ce44466cfa. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call.

About Dentsply Sirona

Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering, including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona's innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Contact Information:

Investors:

Wade Moody

Senior Manager, Investor Relations

Investorrelations@dentsplysirona.com

Press:

Marion Par-Weixlberger

Vice President, Public Relations, Corporate Communications & Brand

Publicrelations@dentsplysirona.com

Forward-Looking Statements and Associated Risks... (truncated)re made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Press Release or to reflect the occurrence of unanticipated events. Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company's SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.

## Financial statements

### Income Statement (Q2 2026 Summary Results (Reported) (in millions, except per share amount and percentages))

| | Q2 26 | Q2 25 | YoY |
|---|---:|---:|---:|
| Net Sales | 898 | 936 | -4.1% |
| Gross Profit | 493 | 490 | 0.6% |
| Gross Margin | 54.9% | 52.4% |  |
| Net Income (Loss) Attributable to Dentsply Sirona | 37 | -45 | NM |
| Diluted Earnings (Loss) Per Share1 | 0.18 | -0.22 | NM |

### Income Statement (Three Months Ended June 30, — (unaudited))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|---:|---:|
| Net sales | 898 | 936 | 1,778 | 1,815 |
| Cost of products sold | 405 | 446 | 858 | 859 |
| Gross profit | 493 | 490 | 920 | 956 |
| Selling, general, and administrative expenses | 364 | 342 | 715 | 700 |
| Research and development expenses | 45 | 37 | 89 | 73 |
| Goodwill and intangible asset impairments |  | 235 |  | 235 |
| Restructuring and other costs | 2 | 4 | 69 | 13 |
| Operating income (loss) | 82 | -128 | 47 | -65 |
| Other income and expenses: | Interest expense, net | 22 | 24 | 46 | 43 |
| Other income and expenses: | Other (income) expense, net | -12 | 1 | -29 | 1 |
| Other income and expenses: | Income (loss) before income taxes | 72 | -153 | 30 | -109 |
| Other income and expenses: | Provision (benefit) for income taxes | 36 | -109 | 4 | -84 |
| Other income and expenses: | Net income (loss) | 36 | -44 | 26 | -25 |
| Other income and expenses: | Less: Net (loss) income attributable to noncontrolling interest | -1 | 1 | -1 |  |
| Other income and expenses: | Net income (loss) attributable to Dentsply Sirona | 37 | -45 | 27 | -25 |
| Earnings (loss) per common share attributable to Dentsply Sirona: | Basic | 0.18 | -0.22 | 0.14 | -0.13 |
| Earnings (loss) per common share attributable to Dentsply Sirona: | Diluted | 0.18 | -0.22 | 0.14 | -0.13 |
| Weighted average common shares outstanding: | Basic | 199.7 | 199.3 | 199.8 | 199.2 |
| Weighted average common shares outstanding: | Diluted | 200.5 | 199.3 | 200.8 | 199.2 |

### Income Statement (Three Months Ended June 30, 2026)

| | Three Months Ended June 30, 2026 – Gross Profit | Three Months Ended June 30, 2026 – Operating Income | Three Months Ended June 30, 2026 – Provision for Income Taxes | Three Months Ended June 30, 2026 – Net Income Attributable to Dentsply Sirona | Three Months Ended June 30, 2026 – Diluted Earnings per Share |
|---|---:|---:|---:|---:|---:|
| Reported | 493 | 82 | 36 | 37 | 0.18 |
| Reported percent net sales | 54.9 | 9.1 |  |  |  |
| Non-GAAP Adjustments: | Amortization of Purchased Intangible Assets | 12 | 49 | 12 | 37 | 0.18 |
| Non-GAAP Adjustments: | Restructuring-Related Charges and Other Costs (a) |  | 10 | 3 | 7 | 0.05 |
| Non-GAAP Adjustments: | Business Combination-Related Costs | 1 | 1 |  | 1 |  |
| Non-GAAP Adjustments: | Income Tax-Related Adjustments (b) |  |  | -21 | 21 | 0.11 |
| Non-GAAP Adjustments: | Adjusted | 506 | 142 | 30 | 103 | 0.52 |
| Non-GAAP Adjustments: | Adjusted percent net sales | 56.4 | 15.8 |  |  |  |

### Income Statement (Three Months Ended June 30, 2025 — Percentages are based on actual values and may not reconcile due to rounding.)

| | Three Months Ended June 30, 2025 – Gross Profit | Three Months Ended June 30, 2025 – Operating (Loss) Income | Three Months Ended June 30, 2025 – (Benefit) Provision for Income Taxes | Three Months Ended June 30, 2025 – Net (Loss) Income Attributable to Dentsply Sirona | Three Months Ended June 30, 2025 – Diluted (Loss) Earnings per Share |
|---|---:|---:|---:|---:|---:|
| Reported | 490 | -128 | -109 | -45 | -0.22 |
| Reported percent net sales | 52.4 | -13.7 |  |  |  |
| Non-GAAP Adjustments: | Amortization of Purchased Intangible Assets | 32 | 54 | 14 | 40 | 0.2 |
| Non-GAAP Adjustments: | Restructuring-Related Charges and Other Costs (a) |  | 5 | 1 | 4 |  |
| Non-GAAP Adjustments: | Goodwill and Intangible Asset Impairments |  | 235 | 21 | 214 | 1.07 |
| Non-GAAP Adjustments: | Business Combination-Related Costs | 1 | 4 | 1 | 3 | 0.01 |
| Non-GAAP Adjustments: | Fair Value and Credit Risk Adjustments |  |  |  | -4 |  |
| Non-GAAP Adjustments: | Income Tax-Related Adjustments (b) |  |  | 107 | -107 | -0.54 |
| Non-GAAP Adjustments: | Adjusted | 523 | 170 | 35 | 105 | 0.52 |
| Non-GAAP Adjustments: | Adjusted percent net sales | 55.9 | 18.2 |  |  |  |

### Income Statement (Three Months Ended June 30, — Reconciliations of reported net income (loss) attributable to Dentsply Sirona to adjusted EBITDA and margin are as follows:)

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 |
|---|---:|---:|
| Net income (loss) attributable to Dentsply Sirona | 37 | -45 |
| Interest expense, net | 22 | 24 |
| (Benefit) provision for income taxes | 36 | -109 |
| Depreciation(1) | 35 | 33 |
| Amortization of intangible assets | 49 | 54 |
| Restructuring-related charges and other costs | 10 | 5 |
| Goodwill and intangible asset impairments |  | 235 |
| Business combination-related costs and fair value adjustments | 1 | 4 |
| Fair value and credit risk adjustments |  | -4 |
| Adjusted EBITDA | 190 | 197 |
| Net sales | 898 | 936 |
| Adjusted EBITDA margin | 21.3 | 21.1 |

### Balance Sheet (June 30, 2026 — (unaudited))

| | June 30, 2026 | December 31, 2025 |
|---|---:|---:|
| Current Assets: | Cash and cash equivalents | 239 | 326 |
| Current Assets: | Accounts and notes receivable-trade, net | 620 | 688 |
| Current Assets: | Inventories, net | 665 | 642 |
| Current Assets: | Prepaid expenses and other current assets | 404 | 367 |
| Current Assets: | Total Current Assets | 1,928 | 2,023 |
| Current Assets: | Property, plant, and equipment, net | 845 | 861 |
| Current Assets: | Operating lease right-of-use assets, net | 129 | 139 |
| Current Assets: | Identifiable intangible assets, net | 870 | 974 |
| Current Assets: | Goodwill | 1,138 | 1,148 |
| Current Assets: | Other noncurrent assets | 294 | 284 |
| Current Assets: | Total Assets | 5,204 | 5,429 |
| Current Liabilities: | Accounts payable | 260 | 300 |
| Current Liabilities: | Accrued liabilities | 664 | 700 |
| Current Liabilities: | Income taxes payable | 33 | 30 |
| Current Liabilities: | Notes payable and current portion of long-term debt | 228 | 313 |
| Current Liabilities: | Total Current Liabilities | 1,185 | 1,343 |

### Cash Flow (Six Months Ended June 30, — (unaudited))

| | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 |
|---|---:|---:|
| Cash flows from operating activities: | Net income (loss) | 26 | -25 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Depreciation | 74 | 68 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Amortization of intangible assets | 90 | 99 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Goodwill asset impairment |  | 156 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Indefinite-lived intangible asset impairment |  | 79 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Deferred income taxes | -42 | -136 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Stock-based compensation expense | 17 | 19 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Other non-cash (income) expense | -13 | 19 |
| Adjustments to reconcile net loss to net cash provided by operating activities: | Gain on disposal of assets | -6 |  |
| Changes in operating assets and liabilities: | Accounts and notes receivable-trade, net | 56 | -31 |
| Changes in operating assets and liabilities: | Inventories, net | -32 | -47 |
| Changes in operating assets and liabilities: | Prepaid expenses and other current assets | -11 | 26 |
| Changes in operating assets and liabilities: | Other noncurrent assets | -2 | 1 |
| Changes in operating assets and liabilities: | Accounts payable | 16 | -10 |
| Changes in operating assets and liabilities: | Accrued liabilities | -38 | -35 |
| Changes in operating assets and liabilities: | Income taxes | 4 | -55 |
| Changes in operating assets and liabilities: | Other noncurrent liabilities |  | -73 |
| Changes in operating assets and liabilities: | Net cash provided by operating activities | 139 | 55 |
| Cash flows from investing activities: | Capital expenditures | -96 | -51 |
| Cash flows from investing activities: | Cash received on derivative contracts |  | 1 |
| Cash flows from investing activities: | Cash paid on derivative contracts |  | -2 |
| Cash flows from investing activities: | Net investment hedge settlements | -8 |  |
| Cash flows from investing activities: | Proceeds from sale of property, plant, and equipment | 5 | 1 |
| Cash flows from investing activities: | Other investing activities | 7 |  |
| Cash flows from investing activities: | Net cash used in investing activities | -92 | -51 |
| Cash flows from financing activities: | Cash paid for treasury stock | -12 |  |
| Cash flows from financing activities: | Proceeds from 364-day bridge loan |  | 435 |
| Cash flows from financing activities: | Repayment of 364-day bridge loan |  | -435 |
| Cash flows from financing activities: | Repayments on short-term borrowings | -50 | -413 |
| Cash flows from financing activities: | Cash dividends paid | -32 | -64 |
| Cash flows from financing activities: | Proceeds from long-term borrowings |  | 550 |
| Cash flows from financing activities: | Repayments on long-term borrowings | -31 | -2 |
| Cash flows from financing activities: | Cash paid for deferred financing costs |  | -13 |
| Cash flows from financing activities: | Other financing activities, net | -5 | -3 |
| Cash flows from financing activities: | Net cash (used in) provided by financing activities | -130 | 55 |
| Cash flows from financing activities: | Effect of exchange rate changes on cash and cash equivalents | -4 | 28 |
| Cash flows from financing activities: | Net (decrease) increase in cash and cash equivalents | -87 | 87 |
| Cash flows from financing activities: | Cash and cash equivalents at beginning of period | 326 | 272 |
| Cash flows from financing activities: | Cash and cash equivalents at end of period | 239 | 359 |
| Supplemental disclosures of cash flow information: | Interest paid, net of amounts capitalized | 43 | 43 |
| Non-cash investing activities: | Property, plant and equipment in accounts payable at end of period | 19 | 25 |
| Non-cash investing activities: | Exchange of inventory for naming and other rights |  | 14 |

### Cash Flow (Three Months Ended June 30, — A reconciliation of free cash flow for the three months ended June 30, 2026 and 2025 is as follows:)

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 |
|---|---:|---:|
| Net cash provided by operating activities | 99 | 48 |
| Capital expenditures | -44 | -32 |
| Free cash flow | 55 | 16 |
